Not available
Quote | Intec Pharma Ltd. (NASDAQ:NTEC)
Last: | $9.63 |
---|---|
Change Percent: | -12.48% |
Open: | $11 |
Close: | $9.63 |
High: | $11.0973 |
Low: | $9.59 |
Volume: | 980,394 |
Last Trade Date Time: | 08/03/2021 04:42:34 am |
News | Intec Pharma Ltd. (NASDAQ:NTEC)
- Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company’s “Pulse-Prime” hypothesis - Dr. Newman also named Chair of the Summit NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a...
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Chief Medical Officer, Roger Waltzman, M.D., will present an update on ...
Message Board Posts | Intec Pharma Ltd. (NASDAQ:NTEC)
Subject | By | Source | When |
---|---|---|---|
znewcar1: NTEC 48% v34M c13.55 f1,842M Was f3.9M about half and Price doubled. | znewcar1 | investorshangout | 07/29/2021 8:27:57 PM |
whytestocks: $NTEC News Article - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers | whytestocks | investorshangout | 05/11/2021 12:05:48 PM |
znewcar1: NTEC 29% v15M c5.96 f3,9M preMH13.7 OH7.49 S5.60 | znewcar1 | investorshangout | 03/15/2021 8:40:57 PM |
znewcar1: NTEC 34% v29,2M c4.64 f3,9M preMH8.7 HOD7.12 then flushed | znewcar1 | investorshangout | 12/09/2020 9:57:54 PM |
whytestocks: $NTEC News Article - Intec Pharma to Present at Oppenheimer Fall Healthcare Life Scienc | whytestocks | investorshangout | 09/14/2020 8:36:01 PM |
News, Short Squeeze, Breakout and More Instantly...
Intec Pharma Ltd. Company Name:
NTEC Stock Symbol:
NASDAQ Market:
- Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company’s “Pulse-Prime” hypothesis - Dr. Newman also named Chair of the Summit NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a...
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Chief Medical Officer, Roger Waltzman, M.D., will present an update on ...
Latest data from first and second cohorts support Company’s 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile Poster Presented at American Society of Clinical Oncology Annual Meeting NEW YORK, June 03, 2024 (GLOBE...